Documento completo  |  Capítulo completo  |  Expandir índice  |  Versión HTML imprimible
Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs
(1999; 61 pages) [French] [Spanish] Ver el documento en el formato PDF
Resumen
These guidelines respond to the WHA requests: They are aimed to provide guidance to Member States in developing their own national measures to combat counterfeiting of drugs. The guidelines provide an overview of the problem and factors contributing to the counterfeiting of drugs. They outline also the steps to be followed in developing national strategies as well the specific measures to be considered in combating counterfeit drugs. Issues such as, approaches to country studies, inspection of suspected counterfeit drugs, screening of potentially counterfeit products and training of human resources are also dealt with in the guidelines.
Índice de contenido
Ver el documentoExecutive Summary
Abrir esta carpeta y ver su contenido1. Introduction
Ver el documento2. Overview of the problem
Ver el documento3. Impact on public health
Ver el documento4. Factors facilitating counterfeiting
Abrir esta carpeta y ver su contenido5. Developing national strategies
Abrir esta carpeta y ver su contenido6. Specific measures
Abrir esta carpeta y ver su contenido7. Assessment of the problem at the national level
Abrir esta carpeta y ver su contenido8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Abrir esta carpeta y ver su contenido9. Test methods
Abrir esta carpeta y ver su contenido10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
Ver el documento11. Conclusion
Ver el documentoReferences
Ver el documentoSelected further reading
Ver el documentoAcknowledgements
Ver el documentoGlossary
 

Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs

Guidelines for the development
of measures to combat
counterfeit drugs

Department of Essential Drugs and
Other Medicines
World Health Organization
Geneva, Switzerland

ORGANISATION MONDIALE DE LA SANTE

WHO/EDM/QSM/99.1
DISTR: GENERAL
ORIGINAL: ENGLISH

This document has been prepared under the auspices of the DMP-DAP Joint Project on Counterfeit Drugs which was administered by the World Health Organization Division of Drug Management and Policies (DMP) and the Action Programme on Essential Drugs (DAP) from 1995 to 1997. With effect from January 1999, the Department of Essential Drugs and Other Medicines Department (EDM) includes the former DAP and most components of DMP.

©World Health Organization (1999)

This document is not a formal publication of the World Health Organization (WHO) and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced, translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The view expressed in documents by named authors are solely the responsibility of those authors.

 

Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019